Literature DB >> 21205257

Use of the AST to platelet ratio index in HCV/HIV co-infected patients.

A G Singal1, L V Thomassen, D R Gretch, M C Shuhart.   

Abstract

BACKGROUND: The AST to platelet ratio index (APRI), a non-invasive marker of liver fibrosis, has not been well studied in HCV/HIV (hepatitis C virus/human immunodeficiency virus) co-infected patients with advanced HIV. AIM: To compare the accuracy of APRI in HCV/HIV co-infected patients to that in HCV mono-infected patients and to determine the impact of CD4+ T-cell counts on its performance.
METHODS: We identified 106 consecutive HCV/HIV co-infected patients and 105 matched HCV mono-infected patients who underwent liver biopsy at Harborview Medical Center over a 5-year period. Performance characteristics were calculated and receiver operating characteristic (ROC) analysis conducted.
RESULTS: The area under the ROC curve (AUROC) of APRI for predicting significant fibrosis was similar when comparing those with and without HIV co-infection (0.77 vs. 0.86, P = 0.18), but was lower in HIV co-infected patients with CD4 counts <250 cells/mm³ (0.64 vs. 0.86, P = 0.05). In HIV co-infected patients with CD4 counts ≥250, APRI had higher negative predictive value (93% vs. 88%, P = 0.57), positive predictive value (63% vs. 40%, P = 0.43) and specificity (95% vs. 88%, P = 0.05) than in those with lower CD4 counts.
CONCLUSIONS: The AST to platelet ratio index (APRI) performance characteristics appear to be suboptimal in HCV/HIV co-infected patients with CD4 counts <250 and they require further study in this population at increased risk for advanced liver disease.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205257      PMCID: PMC3552516          DOI: 10.1111/j.1365-2036.2010.04560.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  38 in total

Review 1.  Noninvasive monitoring of patients with chronic hepatitis C.

Authors:  Robert J Fontana; Anna S F Lok
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 2.  The burden of hepatitis C in the United States.

Authors:  W Ray Kim
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

Authors:  C S Graham; L R Baden; E Yu; J M Mrus; J Carnie; T Heeren; M J Koziel
Journal:  Clin Infect Dis       Date:  2001-07-06       Impact factor: 9.079

4.  Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection.

Authors:  A Pohl; C Behling; D Oliver; M Kilani; P Monson; T Hassanein
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

5.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

6.  Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus.

Authors:  M Puoti; M Bonacini; A Spinetti; V Putzolu; S Govindarajan; S Zaltron; M Favret; F Callea; F Gargiulo; F Donato; G Carosi
Journal:  J Infect Dis       Date:  2000-11-16       Impact factor: 5.226

7.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

8.  Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

Authors:  Robert P Myers; Yves Benhamou; Françoise Imbert-Bismut; Vincent Thibault; Marie Bochet; Frédéric Charlotte; Vlad Ratziu; François Bricaire; Christine Katlama; Thierry Poynard
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

Review 9.  Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C.

Authors:  J O Smith; R K Sterling
Journal:  Aliment Pharmacol Ther       Date:  2009-06-10       Impact factor: 8.171

10.  Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients.

Authors:  A H Mohsen; P J Easterbrook; C Taylor; B Portmann; R Kulasegaram; S Murad; M Wiselka; S Norris
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  9 in total

Review 1.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

2.  Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis.

Authors:  Jason Martin; Gaurav Khatri; Purva Gopal; Amit G Singal
Journal:  Dig Dis Sci       Date:  2015-01-14       Impact factor: 3.199

Review 3.  Assessment of liver disease (noninvasive methods).

Authors:  Shruti H Mehta; Geoffrey C Buckle
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

4.  Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.

Authors:  Bevin Hearn; David Delbello; Joseph Lawler; Michel Ng; Alyson Harty; Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

5.  Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-02       Impact factor: 11.382

Review 6.  Non-invasive diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Leonardo de Lucca Schiavon; Janaína Luz Narciso-Schiavon; Roberto José de Carvalho-Filho
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 7.  Role of liver biopsy in the era of direct-acting antivirals.

Authors:  Humberto C Gonzalez; Syed Mohammed Jafri; Stuart C Gordon
Journal:  Curr Gastroenterol Rep       Date:  2013-02

8.  Direct and Indirect Serum Markers of Liver Fibrosis Compared with Transient Elastography among Women in the Women's Interagency HIV Study.

Authors:  Seble Kassaye; Ying Li; Gregory Huhn; Marion G Peters; Audrey L French; Phyllis C Tien; Bruce Luxon; Michael W Plankey
Journal:  J AIDS Clin Res       Date:  2015-04

9.  Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection.

Authors:  Barbara Rossetti; Valentina Borgo; Arianna Emiliozzi; Marta Colaneri; Giacomo Zanelli; Miriana d'Alessandro; Davide Motta; Laura Maiocchi; Francesca Montagnani; Maria Cristina Moioli; Chiara Baiguera; Margherita Sambo; Teresa Chiara Pieri; Pietro Valsecchi; Raffaele Bruno; Massimo Puoti; Massimiliano Fabbiani
Journal:  Diagnostics (Basel)       Date:  2021-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.